Related Experiment Video
Updated: Jun 26, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
CpG oligonucleotide as an adjuvant for the treatment of prostate cancer
1Department of Urology, University of Iowa, Iowa City, 52242, United States. david-lubaroff@uiowa.edu
Abstract:
The use of an adenovirus transduced to express a prostate cancer antigen (PSA) as a vaccine for the treatment of prostate cancer has been shown to be active in the destruction of antigen-expressing prostate tumor cells in a pre-clinical model, using Balb/C or PSA transgenic mice. The destruction of PSA-secreting mouse prostate tumors was observed in Ad/PSA immunized mice in a prophylaxis study with 70% of the mice surviving long term tumor free. This successful immunotherapy was not observed in therapeutic studies in which tumors were established before vaccination and the development of anti-PSA immune response was not as easily generated in PSA transgenic mice. Immunization of conventional and transgenic animals was enhanced by incorporating a collagen matrix into the immunizing injection. Therefore the need to strengthen anti-PSA and anti-prostate cancer immunity was an obvious next step in developing a successful prostate cancer immunotherapy. Because the use of immunostimulatory CpG motifs was shown to enhance immune responses to a wide variety of antigens, our studies incorporated CpG into the Ad/PSA vaccine experimental plans. The results of the subsequent studies demonstrated a dichotomy where Ad/PSA plus CpG enhanced the in vivo destruction of PSA-secreting tumors and the survival of experimental animals, but revealed that the number and in vitro activities of antigen specific CD8+ T cells was decreased as compared to the values observed when the vaccine alone was used for immunization. The dichotomous observations were confirmed using another antigen system, OVA also incorporated into a replication defective adenovirus. Despite the reduction in antigen-specific CD8+ cells after vaccine plus CpG immunization the enhanced destruction of sc and systemic tumors was shown to be mediated entirely by CD8+ T cells. Finally, the reduction of the CD8+ T cells was the result of an observed decrease in the proliferation of the antigen specific cell population.
Insights
Adding CpG motifs to an adenovirus-based prostate cancer vaccine (Ad/PSA) enhanced tumor destruction and survival but paradoxically reduced CD8+ T cell proliferation, despite CD8+ T cells mediating the therapeutic effect.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Adenovirus-vectored vaccines expressing prostate-specific antigen (PSA) show promise for prostate cancer immunotherapy.
- Pre-clinical models demonstrated Ad/PSA vaccine efficacy in prophylaxis but not in established tumors.
- Enhancing anti-tumor immunity is crucial for developing effective prostate cancer immunotherapies.
Purpose of the Study:
- To investigate the impact of immunostimulatory CpG motifs on Ad/PSA vaccine efficacy and immune responses.
- To evaluate the role of CD8+ T cells in Ad/PSA plus CpG mediated anti-tumor activity.
- To understand the mechanisms behind the observed immune response dichotomy.
Main Methods:
- Adenovirus vectors expressing PSA (Ad/PSA) or ovalbumin (OVA) were used in pre-clinical mouse models.
- CpG motifs were incorporated into the Ad/PSA vaccine formulation.
- Tumor destruction, animal survival, and antigen-specific CD8+ T cell populations (number and activity) were assessed.
- T cell proliferation assays were conducted to investigate immune cell dynamics.
Main Results:
- Ad/PSA plus CpG vaccination enhanced in vivo tumor destruction and prolonged survival compared to Ad/PSA alone.
- A significant decrease in the number and in vitro activity of antigen-specific CD8+ T cells was observed with Ad/PSA plus CpG.
- Despite reduced CD8+ T cell numbers, these cells were confirmed to mediate the enhanced anti-tumor effects.
- The reduction in CD8+ T cells was attributed to decreased proliferation of antigen-specific T cells.
Conclusions:
- Immunostimulatory CpG motifs can enhance the therapeutic efficacy of Ad/PSA vaccines against prostate cancer.
- A complex interplay exists between CpG adjuvantation, CD8+ T cell responses, and anti-tumor immunity.
- Further research is needed to optimize vaccine strategies that balance potent anti-tumor effects with robust T cell immunity.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
GPCRs Regulate Adenylyl Cylase Activity
Two...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

